PMP22 and ganglioneuroma: In South Africa, limited genetic testing is available for non-muscle NMD and includes only PMP22 multiplex ligation-dependent probe amplification (MLPA) for GN and spinocerebellar ataxias 1, 2, 3, 6, 7, 12, 17 and Frataxin expansion screening for spastic ataxias.